Published in Nat Med on February 06, 2013
WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med (2013) 2.91
Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB. Nat Med (2014) 2.30
Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci U S A (2015) 2.25
Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. N Engl J Med (2016) 2.15
The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell (2015) 1.91
HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J Bone Miner Res (2015) 1.60
Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells. Blood (2015) 1.50
Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat Med (2014) 1.39
Fracture healing: mechanisms and interventions. Nat Rev Rheumatol (2014) 1.33
The Interplay between the bone and the immune system. Clin Dev Immunol (2013) 1.26
Osteoclasts: more than 'bone eaters'. Trends Mol Med (2014) 1.17
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res (2014) 1.14
Regulation of gene expression by 1,25-dihydroxyvitamin D3 in bone cells: exploiting new approaches and defining new mechanisms. Bonekey Rep (2014) 1.10
Regulation of Wnt/β-catenin signaling within and from osteocytes. Bone (2013) 1.08
Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer. Nat Neurosci (2014) 1.05
Interplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritis. Int J Mol Sci (2013) 1.00
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics. Stem Cells Int (2013) 0.98
Emerging targets in osteoarthritis therapy. Curr Opin Pharmacol (2015) 0.97
The rachitic tooth. Endocr Rev (2013) 0.96
A trans-ethnic genome-wide association study identifies gender-specific loci influencing pediatric aBMD and BMC at the distal radius. Hum Mol Genet (2015) 0.96
WNT signaling in bone development and homeostasis. Wiley Interdiscip Rev Dev Biol (2014) 0.95
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res (2015) 0.95
Wnt signaling in cancer. Oncogene (2016) 0.95
Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed) (2014) 0.94
Estrogen receptor α in osteocytes regulates trabecular bone formation in female mice. Bone (2013) 0.94
Understanding of dopant-induced osteogenesis and angiogenesis in calcium phosphate ceramics. Trends Biotechnol (2013) 0.93
SOXC proteins amplify canonical WNT signaling to secure nonchondrocytic fates in skeletogenesis. J Cell Biol (2014) 0.92
Dental and periodontal phenotype in sclerostin knockout mice. Int J Oral Sci (2014) 0.92
Sclerostin Inhibition in the Management of Osteoporosis. Calcif Tissue Int (2016) 0.92
Noncanonical Wnt5a enhances Wnt/β-catenin signaling during osteoblastogenesis. Sci Rep (2014) 0.91
Genetics of Bone Mass in Childhood and Adolescence: Effects of Sex and Maturation Interactions. J Bone Miner Res (2015) 0.91
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Res (2016) 0.91
Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos Int (2014) 0.90
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A (2014) 0.90
Bone: Romosozumab - getting there but not quite yet. Nat Rev Endocrinol (2016) 0.89
From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol (2015) 0.89
Epigenetic modifications and canonical wingless/int-1 class (WNT) signaling enable trans-differentiation of nonosteogenic cells into osteoblasts. J Biol Chem (2014) 0.89
Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Oncotarget (2015) 0.89
Wnt signaling regulates pulp volume and dentin thickness. J Bone Miner Res (2014) 0.89
Sirtuin1 (Sirt1) promotes cortical bone formation by preventing β-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem (2014) 0.88
Effects of Combined Exposure to Lead and High-Fat Diet on Bone Quality in Juvenile Male Mice. Environ Health Perspect (2015) 0.88
Wnt signaling and osteoporosis. Maturitas (2014) 0.88
The Wnt serpentine receptor Frizzled-9 regulates new bone formation in fracture healing. PLoS One (2013) 0.88
The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res (2014) 0.88
Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int (2015) 0.87
The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations. Hum Mol Genet (2014) 0.87
Wnt signaling regulates homeostasis of the periodontal ligament. J Periodontal Res (2014) 0.87
Factors and mechanisms involved in the coupling from bone resorption to formation: how osteoclasts talk to osteoblasts. J Bone Metab (2014) 0.86
Structure-function analysis of the C-clamp of TCF/Pangolin in Wnt/ß-catenin signaling. PLoS One (2014) 0.86
The effect of low-magnitude whole body vibration on bone density and microstructure in men and women with chronic motor complete paraplegia. J Spinal Cord Med (2014) 0.86
Wnt signaling in bone and muscle. Bone (2015) 0.86
Biological agents in management of osteoporosis. Eur J Clin Pharmacol (2014) 0.86
Updating the Wnt pathways. Biosci Rep (2014) 0.86
Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol (2014) 0.86
Diametrical diseases reflect evolutionary-genetic tradeoffs: Evidence from psychiatry, neurology, rheumatology, oncology and immunology. Evol Med Public Health (2015) 0.85
Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. Proc Natl Acad Sci U S A (2015) 0.85
Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials. Biomed Res Int (2014) 0.85
Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways. Arthritis Res Ther (2015) 0.85
Sequence variants in the PTCH1 gene associate with spine bone mineral density and osteoporotic fractures. Nat Commun (2016) 0.84
Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives. Clin Interv Aging (2015) 0.84
The role of midkine in skeletal remodelling. Br J Pharmacol (2014) 0.84
Dynamics of bone healing after osteotomy with piezosurgery or conventional drilling - histomorphometrical, immunohistochemical, and molecular analysis. J Transl Med (2013) 0.84
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone (2015) 0.83
Activation of Wnt Signaling by Mechanical Loading Is Impaired in the Bone of Old Mice. J Bone Miner Res (2016) 0.83
Rescuing failed oral implants via Wnt activation. J Clin Periodontol (2016) 0.83
Regulation of bone metabolism by Wnt signals. J Biochem (2015) 0.83
Induced ablation of Bmp1 and Tll1 produces osteogenesis imperfecta in mice. Hum Mol Genet (2014) 0.83
Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling. Cell Death Dis (2014) 0.83
The osteocyte: key player in regulating bone turnover. RMD Open (2015) 0.83
Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior. Neurosci Biobehav Rev (2014) 0.83
Wnt16 Is Associated with Age-Related Bone Loss and Estrogen Withdrawal in Murine Bone. PLoS One (2015) 0.83
Exploiting endogenous fibrocartilage stem cells to regenerate cartilage and repair joint injury. Nat Commun (2016) 0.83
Predicting and validating the pathway of Wnt3a-driven suppression of osteoclastogenesis. Cell Signal (2014) 0.83
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health (2015) 0.83
Wnt signaling in cartilage development and diseases: lessons from animal studies. Lab Invest (2015) 0.82
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. J Bone Miner Res (2016) 0.82
The osteocyte as a therapeutic target in the treatment of osteoporosis. Ther Adv Musculoskelet Dis (2014) 0.82
The genetics of bone mass and susceptibility to bone diseases. Nat Rev Rheumatol (2016) 0.82
T cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment. J Bone Miner Res (2015) 0.81
Bone Regulates Glucose Metabolism as an Endocrine Organ through Osteocalcin. Int J Endocrinol (2015) 0.81
Regulatory-auxiliary subunits of CLC chloride channel-transport proteins. J Physiol (2015) 0.81
Chromomycins A2 and A3 from marine actinomycetes with TRAIL resistance-overcoming and Wnt signal inhibitory activities. Mar Drugs (2014) 0.81
Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing. PLoS One (2015) 0.81
Identification of MicroRNA for Intermuscular Bone Development in Blunt Snout Bream (Megalobrama amblycephala). Int J Mol Sci (2015) 0.81
PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases. Clin Sci (Lond) (2015) 0.81
Bone mineral density in children with fanconi anemia after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2015) 0.81
Osteoimmunology and bone homeostasis: relevance to spondyloarthritis. Curr Rheumatol Rep (2013) 0.81
Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev (2017) 0.81
Wnt/β-catenin signaling mediates osteoblast differentiation triggered by peptide-induced α5β1 integrin priming in mesenchymal skeletal cells. J Biol Chem (2015) 0.81
The impact of low-magnitude high-frequency vibration on fracture healing is profoundly influenced by the oestrogen status in mice. Dis Model Mech (2014) 0.80
Lgr6 marks nail stem cells and is required for digit tip regeneration. Proc Natl Acad Sci U S A (2015) 0.80
N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action. J Bone Miner Res (2015) 0.80
Casein kinase 1 α phosphorylates the Wnt regulator Jade-1 and modulates its activity. J Biol Chem (2014) 0.80
Mineralisation of collagen rich soft tissues and osteocyte lacunae in Enpp1(-/-) mice. Bone (2014) 0.80
Wnt/β-catenin signaling modulates human airway sensitization induced by β2-adrenoceptor stimulation. PLoS One (2014) 0.80
Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine. J Bone Miner Metab (2015) 0.80
Signature of microRNA expression during osteogenic differentiation of bone marrow MSCs reveals a putative role of miR-335-5p in osteoarthritis. BMC Musculoskelet Disord (2015) 0.80
A unified model for bone-renal mineral and energy metabolism. Curr Opin Pharmacol (2015) 0.80
Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations. J Clin Endocrinol Metab (2014) 0.80
Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading. J Biol Chem (2015) 0.80
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 19.60
Mutations affecting segment number and polarity in Drosophila. Nature (1980) 18.72
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science (1991) 9.89
Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell (1982) 9.29
Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell (2005) 8.16
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development (2006) 7.08
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet (2008) 7.05
Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell (2005) 6.90
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
Multiple genetic loci for bone mineral density and fractures. N Engl J Med (2008) 6.35
LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development (2004) 6.21
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol (2002) 6.20
Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science (1991) 6.15
Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature (2011) 6.09
Towards an integrated view of Wnt signaling in development. Development (2009) 6.07
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell (2008) 5.93
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Lrp5 functions in bone to regulate bone mass. Nat Med (2011) 5.33
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
The amazing osteocyte. J Bone Miner Res (2011) 5.32
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet (2009) 5.32
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet (2001) 4.97
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem (2007) 4.74
R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A (2011) 4.52
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J (2003) 4.32
LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science (2007) 4.27
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem (2005) 4.13
Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet (2010) 4.08
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet (2002) 4.00
Retracted A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol (2007) 3.97
Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development (2004) 3.89
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med (2004) 3.88
Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res (2009) 3.69
Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res (2009) 3.66
Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell (2008) 3.62
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J (2005) 3.61
Osteocytes, mechanosensing and Wnt signaling. Bone (2008) 3.57
Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol (2011) 3.51
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med (2012) 3.46
Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium (2005) 3.46
Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res (2006) 3.44
New sequence variants associated with bone mineral density. Nat Genet (2008) 3.43
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res (2011) 3.25
R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A (2007) 3.24
Endocrine regulation of male fertility by the skeleton. Cell (2011) 3.20
Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem (2006) 3.10
The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol (2004) 3.09
Wnt-14 plays a pivotal role in inducing synovial joint formation in the developing appendicular skeleton. Cell (2001) 3.06
The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem (2006) 3.04
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Wnt3a-/--like phenotype and limb deficiency in Lef1(-/-)Tcf1(-/-) mice. Genes Dev (1999) 2.94
Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet (2003) 2.86
Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol (2010) 2.85
Dorsalizing signal Wnt-7a required for normal polarity of D-V and A-P axes of mouse limb. Nature (1995) 2.73
Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A (2005) 2.67
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res (2005) 2.61
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res (2006) 2.61
Mouse cristin/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression. J Biol Chem (2006) 2.61
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006) 2.59
Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev (2009) 2.57
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA (2008) 2.52
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res (2004) 2.46
Wnt signaling from development to disease: insights from model systems. Cold Spring Harb Perspect Biol (2009) 2.42
Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell (2007) 2.41
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Denosumab and bisphosphonates: different mechanisms of action and effects. Bone (2010) 2.37
Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem (2007) 2.37
Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev (2008) 2.22
Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res (2010) 2.19
Wnt/beta-catenin signaling is sufficient and necessary for synovial joint formation. Genes Dev (2004) 2.18
Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet (2005) 2.10
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood (2008) 2.05
Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol (2008) 2.04
Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol (2005) 2.00
Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab (2010) 1.98
Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab (2004) 1.95
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms. J Biol Chem (2005) 1.85
Mutations in WNT7A cause a range of limb malformations, including Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome. Am J Hum Genet (2006) 1.85
Wntless functions in mature osteoblasts to regulate bone mass. Proc Natl Acad Sci U S A (2012) 1.85
Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem (2007) 1.79
Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet (2000) 1.77
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol (2010) 2.85
Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol (2008) 2.85
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res (2005) 2.61
Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res (2010) 2.19
High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol (2002) 1.95
Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res (2007) 1.74
Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci U S A (2012) 1.68
Mef2c deletion in osteocytes results in increased bone mass. J Bone Miner Res (2012) 1.68
Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem (2011) 1.63
Sclerostin deficiency is linked to altered bone composition. J Bone Miner Res (2014) 1.49
Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res (2014) 1.42
Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab (2010) 1.29
Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res (2013) 1.08
Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and chondrocyte hypertrophy in bone. Bone (2009) 1.02
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res (2015) 0.95
Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol (2007) 0.91
Isolation of mouse osteocytes using cell fractionation for gene expression analysis. Methods Mol Biol (2012) 0.85
ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone (2011) 0.82
Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J Clin Invest (2016) 0.80
1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists. J Med Chem (2010) 0.78
Histomorphometrical and clinical comparison of submerged and nonsubmerged implants subjected to experimental peri-implantitis in dogs. Clin Oral Implants Res (2004) 0.78
Studying gene expression in bone by in situ hybridization. Methods Mol Biol (2012) 0.77
Preface: the osteocyte. Bone (2013) 0.77
Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists). Bioorg Med Chem Lett (2010) 0.75